| Jonathan Ayers, chairman and CEO of IDEXX Laboratories, has adopted, on November 3, 2009, a securities trading plan designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The plan covers a portion of a stock option granted to Ayers in January 2002 that will expire in January 2012. Under the plan, Ayers may exercise, under pre-arranged terms, options to purchase up to 600,000 shares of IDEXX common stock and sell a portion of the shares received on exercise. Of the shares acquired on exercise, Ayers will retain shares having a value equal to approximately 50% of the spread between the market price of the stock and the option exercise price, after taxes and transaction expenses. He intends to sell the remaining shares to cover the exercise price, transaction expenses and taxes and to diversify his assets. :theflyonthewall.com |
Subscribe for More Information